Literature DB >> 12851020

Disulfiram treatment for alcoholism in severe mental illness.

Kim T Mueser1, Douglas L Noordsy, Lindy Fox, Rosemarie Wolfe.   

Abstract

Controlled research has shown that supervised disulfiram is an effective treatment for alcoholism. Despite this, little is known about the effects of disulfiram in persons with alcoholism and severe mental illness. We conducted comprehensive chart reviews on 33 patients with alcoholism and severe mental illness (70% schizophrenia or schizoaffective disorder) who had been prescribed disulfiram. Twenty-one percent reported side effects from disulfiram, whereas significant psychiatric complications were not reported. Although 76% of patients reported drinking while on disulfiram, only 28% experienced negative reactions to alcohol. Sixty-four percent of the patients saw a remission of alcoholism for at least one year during a three-year follow-up, and 30% experienced a two-year remission. Disulfiram treatment was associated with decreases in days hospitalized but not with changes in work status. The results suggest disulfiram may be a useful adjunctive treatment for alcoholism in patients with severe mental illness and that controlled research is needed to evaluate its effects in this population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12851020

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  17 in total

Review 1.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 2.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 3.  [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

Authors:  T Wobrock; R D'Amelio; P Falkai
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

Review 4.  Pharmacological treatment of schizophrenia and co-occurring substance use disorders.

Authors:  David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Delirium-associated disulfiram and ethanol interactions.

Authors:  Hasan Mirsal; Irem Yalug; Devran Tan; Theodore A Stern; Ayhan Kalyoncu; Ozkan Pektas; Gamze Erdogan; Mansur Beyazyürek
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

6.  Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram.

Authors:  Ismene L Petrakis; Charla Nich; Elizabeth Ralevski
Journal:  Schizophr Bull       Date:  2006-08-03       Impact factor: 9.306

7.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

8.  Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.

Authors:  Ismene L Petrakis; Stephanie O'Malley; Bruce Rounsaville; James Poling; Colette McHugh-Strong; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

Review 9.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Douglas L Noordsy; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

Review 10.  Integrated treatment of substance use and psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley
Journal:  Soc Work Public Health       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.